Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt: 2014-2025

Historic Short term Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 1 years, with Jun 2025 value amounting to $8.4 million.

  • Viridian Therapeutics, Inc.\DE's Short term Debt rose 184.58% to $8.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $8.4 million, marking a year-over-year increase of 184.58%. This contributed to the annual value of $1.0 million for FY2014, which is N/A change from last year.
  • As of Q2 2025, Viridian Therapeutics, Inc.\DE's Short term Debt stood at $8.4 million, which was up 184.58% from $3.0 million recorded in Q2 2024.
  • Viridian Therapeutics, Inc.\DE's 5-year Short term Debt high stood at $8.4 million for Q2 2025, and its period low was $3.0 million during Q2 2024.
  • Moreover, its 2-year median value for Short term Debt was $5.7 million (2024), whereas its average is $5.7 million.
  • Data for Viridian Therapeutics, Inc.\DE's Short term Debt shows a peak YoY skyrocketed of 184.58% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Viridian Therapeutics, Inc.\DE's Short term Debt stood at $3.0 million in 2024, then spiked by 184.58% to $8.4 million in 2025.
  • Its Short term Debt stands at $8.4 million for Q2 2025, versus $3.0 million for Q2 2024 and $1.0 million for Q4 2014.